Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study

被引：0

作者：

Narezkina, Anna ^{[1
]}

Akhter, Nausheen ^{[2
]}

Lu, Xiaoxiao ^{[3
]}

Emond, Bruno ^{[4
]}

Huang, Qing ^{[3
]}

Panjabi, Sumeet ^{[3
]}

Hilts, Annalise ^{[4
]}

Lu, Stephanie ^{[5
]}

Lafeuille, Helene ^{[4
]}

Lafeuille, Marie-Helene ^{[4
]}

Choi, Michael ^{[6
]}

机构：

[1] Univ Calif San Diego Hlth, San Diego, CA USA

[2] Northwestern Med, Chicago, IL USA

[3] Janssen Sci Affairs LLC, Horsham, PA USA

[4] Anal Grp Inc, Montreal, PQ, Canada

[5] Anal Grp Inc, Menlo Pk, CA USA

[6] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

CLL; chronic lymphocytic leukemia/small lymphocytic lymphoma; Bruton's tyrosine kinase inhibitor; time to next treatment; treatment persistence; atrial fibrillation;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CLL-390

引用

页码：S276 / S277

页数：2